Abstract: Modified or extended release formulations containing tolterodine and associated methods are disclosed and described. Methods for making and administering said modified release formulations are also disclosed.

Abstract: A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt compositions are formed by molding or compression, with an additional heating step being preferred.

Abstract: The invention relates to a modified release (e.g., extended release) tablet composition for oral administration comprising: (a) a dihydropyridine compound or a prodrug or salt thereof; (b) a first release control agent; (c) a second release control agent; and (d) a third release control agent; wherein said second release control agent has a higher viscosity than said first release control agent. The invention also relates to methods for making such modified release (e.g., extended release) tablet compositions. After tableting, such compositions exhibit a release profile that is approximately zero order without the need of a coating.

Abstract: A platform architecture shifts the networked computing paradigm from PC+Network to a system using trusted mobile internet end-point (MIEP) devices and cooperative agents hosted on a trusted server. The MIEP device can participate in data flows, arbitrate authentication, and/or participate in implementing security mechanisms, all within the context of assured end-to-end security. The MIEP architecture improves platform-level capabilities by suitably (and even dynamically) partitioning what is done at the MIEP nodes, the network, and the server based infrastructure for delivering services.

Abstract: A method and a system to application configuration across client devices of a local system are disclosed. An exemplary embodiment provides a method for sharing of an application configuration data across client devices. A local storage device of a local system is updated to comprise an application from a remote storage device of a cloud computing system. The application is accessed from the local storage device. The application with a local processing device is implemented without installing the application on the local processing device when requested by the local processing device. Set of function calls are emulated between the application on the local storage device and an operating system of the local processing device.

Abstract: Modified release diltiazem compositions and associated methods of preparation and administration are provided.

Abstract: Modified release niacin formulations, methods for making the formulations, and methods of using the formulations.

Abstract: A method, apparatus and system of centralized management of applications and desktop preferences without requiring configuration of client-side operating systems are disclosed. In one embodiment, a method of a rich client device includes accessing an application installed on a server, and executing the application from the rich client device without installing the application on the rich client device (e.g., that may mean that an operating system of the rich client device is not modified to perform the function calls between the application and the operating system) when requested by a user of the rich client device through a binary module (e.g., the binary module may include required resources between the application and the operating system including a file system data, a Dynamic-Link library (DLL) data, etc.) of the server that emulates a set of function calls between the application and an operating system of the rich client device.

Abstract: Modified or extended release formulations containing mesalamine compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved mesalamine formulations such as PENTASA®.

Abstract: Solid dose rapidly disintegrating compositions for administering pharmaceutical and nutritional supplement agents and methods for the preparation thereof are disclosed and described. Preparation methods which maintain the particulate size of an active agent at the pre-processing size in the final composition are further disclosed. The ability to maintain such particulate size provides a number of advantages, including improved bioavailability and more accurate dosing.

Abstract: A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt compositions are formed by molding or compression, with an additional heating step being preferred.

Abstract: A novel rapid-melt, semi-solid molded composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal wherein the prophylactic or therapeutic active is a psychotropic, a gastrointestinal therapeutic or a migraine therapeutic.

Abstract: A novel extended or controlled release encapsulated product is provided and includes: a pharmaceutically effective amount of fluoxetine HCl or mesalamine; at least one erodible polymer; and at least one lubricating material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A pulsating release product for extended release of fluoxetine is also disclosed. A method for preparing the encapsulated product is also provided.

Abstract: A novel encapsulated product is provided and includes: at least one active ingredient; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided. The encapsulated product may be incorporated into a food item, a confectionery product or chewing gum product.

Abstract: A sugar-free composition comprising a mixture of at least two polyols present in an amount from about 15 to 80% by weight, an emulsifier system present in an amount from about 1.0 to 30% by weight, an active agent in an amount from about 0.1 to 70% by weight and water in an amount from 0 to 15% by weight with optional components comprising colors, flavors and binders totalling 100%. Also, a method of preparing a sugar-free composition comprising the steps of mixing from about 15 to 80% by weight of at least two polyols with about 0 to 15% by weight water, heating the mixture to about 200-260° F. for about 5 to 10 minutes, cooling the mixture to about 175-240° F., adding to the mixture about 1.0 to 30% by weight an emulsifier system to form a further mixture, cooling the further mixture to about 100-110° F., and adding to the cooled further mixture about 0.1 to 70% by weight of an active ingredient to form the sugar-free composition.

Abstract: A novel process for preparing a stable solid delivery system in which the steps include: blending about 30.0 to 90.0% by weight a carbohydrate component with about 2.0 to 12.0% by weight a humectant component and remainder water in a heating vessel to form a mixture; heating the mixture to a final temperature of about 150° F. to about 300° F. to form a cooked mixture; cooling the cooked mixture while continually mixing to a temperature of about 175° F. to 250° F. to form a cooled mixture; blending about 0.5 to 30.0% by weight of an emulsifier system; maintaining a temperature of about 175° F. to 250° F. and blending said emulsifier system with the cooled mixture to form a delivery base; cooling the delivery base to a temperature below about 110° F. to form a stable solid delivery system; and mixing the stable solid delivery system with at least one active agent.

Abstract: A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt compositions are formed by molding or compression, with an additional heating step being preferred.

Abstract: A novel rapid-melt, semi-solid molded composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal wherein the prophylactic or therapeutic active is a psychotropic, a gastrointestinal therapeutic or a migraine therapeutic.

Abstract: A novel rapid-melt, semi-solid molded composition including at least one binder in an amount from about 0.01% to about 70% by weight; a salivating agent in an amount from about 0.05% to about 15% by weight, a diluent/bulking material in an amount from about 10% to about 90% by weight; and an active material in an amount from about 0.001% to about 70% by weight. Further, the inventive subject matter includes a method of preparing a rapid-melt, semi-solid molded composition comprising the steps of: melting at least one binder in an amount from about 0.01% to about 70% by weight with a salivating agent in an amount from about 0.05% to about 15% by weight, to form a mixture; mixing an active material with said mixture to form an active mixture; mixing a diluent/bulking material with said active mixture to form a final mixture; and molding said final mixture into said semi-solid molded composition.

Abstract: A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided.